{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:10:49Z","timestamp":1779887449245,"version":"3.53.1"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Accurate interpretation of hepatitis B virus (HBV) polymerase sequences is essential for identifying antiviral resistance, particularly for high-genetic-barrier agents such as entecavir. Current resistance interpretation relies largely on deterministic rule-based systems that do not quantify uncertainty and are difficult to evaluate across independent datasets. We aimed to develop and externally validate a transparent probabilistic framework for reconstructing a predefined entecavir resistance pathway from HBV polymerase sequences. Methods: HBV polymerase sequences were retrieved from the NCBI GenBank database and curated through translation, quality control, and deduplication to create the development dataset. Reverse transcriptase (RT) positions were indexed using motif-anchored numbering based on the YMDD-family motif. A genotypic proxy for the entecavir resistance pathway was defined by lamivudine-associated background substitutions combined with entecavir-associated RT substitutions. A logistic regression model with probability calibration was trained and internally validated using prespecified performance metrics and thresholds. External validation was performed on an independent HBVdb dataset with preprocessing, model parameters, and thresholds frozen prior to evaluation. Results: The development dataset comprised 1174 unique polymerase sequences, of which 268 met the resistance pathway definition. Internal validation demonstrated perfect discrimination, consistent with the deterministic genotypic definition of the outcome. External validation on 11,513 independent HBVdb sequences demonstrated reproducible performance across repositories despite a markedly lower prevalence of the resistance pathway (2.2%), with preserved discrimination and stable threshold-based performance. Conclusions: This study presents a transparent and externally validated machine learning framework for probabilistic identification of the entecavir resistance pathway in HBV. The approach provides a transparent and reproducible probabilistic formalization of an established genotypic resistance definition and may serve as a methodological framework for standardized sequence-based resistance interpretation.<\/jats:p>","DOI":"10.3390\/v18060610","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:31:56Z","timestamp":1779885116000},"page":"610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Externally Validated Probabilistic Modeling of a Predefined Entecavir Resistance Pathway in HBV Using Independent Public Repositories"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5402-3160","authenticated-orcid":false,"given":"Christelos","family":"Kapatais","sequence":"first","affiliation":[{"name":"1st Department of Respiratory Medicine, Sotiria Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanie","family":"Karaoulani","sequence":"additional","affiliation":[{"name":"Biopathological-Biochemical Department, Psychiatric Hospital of Attica \u201cDromokaiteio\u201d, 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios P.","family":"Fortis","sequence":"additional","affiliation":[{"name":"Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Street, 12243 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matina","family":"Saritzoglou","sequence":"additional","affiliation":[{"name":"3rd Department of Pathology, Sotiria Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Martsoukos","sequence":"additional","affiliation":[{"name":"Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Ag. Spyridonos Street, 12243 Athens, Greece"},{"name":"1st Department of Internal Medicine, General Hospital of Nikea \u201cAgios Panteleimon\u201d, 18454 Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kapatais","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, General Hospital of West Attica \u201cAgia Varvara\u201d, 12351 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2026, February 10). Global Hepatitis Report 2017. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241565455."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B Virus Resistance to Nucleo(s)tide Analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.antiviral.2009.12.006","article-title":"Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-na\u00efve Chinese patients","volume":"85","author":"Liu","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gks1022","article-title":"HBVdb: A knowledge database for Hepatitis B Virus","volume":"41","author":"Hayer","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2017.18391","article-title":"Big Data and Machine Learning in Health Care","volume":"319","author":"Beam","year":"2018","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jamia\/ocw042","article-title":"Opportunities and challenges in developing risk prediction models with electronic health records data: A systematic review","volume":"24","author":"Goldstein","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"m1328","DOI":"10.1136\/bmj.m1328","article-title":"Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal","volume":"369","author":"Wynants","year":"2020","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: A framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: A novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"D29","DOI":"10.1093\/nar\/gkac1032","article-title":"Database resources of the National Center for Biotechnology Information in 2023","volume":"51","author":"Sayers","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(19)30037-6","article-title":"Reporting of artificial intelligence prediction models","volume":"393","author":"Collins","year":"2019","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside na\u00efve patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Walsh, A.W., Langley, D.R., Colonno, R.J., and Tenney, D.J. (2010). Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009195"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.75.10.4771-4779.2001","article-title":"Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emtricitabine","volume":"75","author":"Das","year":"2001","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1128\/AAC.01499-06","article-title":"The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro","volume":"51","author":"Warner","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","article-title":"Evolution of multi-drug resistant hepatitis B virus during sequential therapy","volume":"44","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: Mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000361076","article-title":"Hepatitis B virus drug resistance tools: One sequence, two predictions","volume":"57","author":"Beggel","year":"2014","journal-title":"Intervirology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gky349","article-title":"geno2pheno[ngs-freq]: A genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data","volume":"46","author":"Friedrich","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105711","DOI":"10.1016\/j.jcv.2024.105711","article-title":"A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir","volume":"174","author":"Lumley","year":"2024","journal-title":"J. Clin. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jclinepi.2015.12.005","article-title":"A calibration hierarchy for risk models was defined: From utopia to empirical data","volume":"74","author":"Nieboer","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1136\/bmj.i6","article-title":"Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests","volume":"352","author":"Vickers","year":"2016","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis: Explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1002\/sim.9025","article-title":"Minimum sample size for external validation of a clinical prediction model with a binary outcome","volume":"40","author":"Riley","year":"2021","journal-title":"Stat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:47:02Z","timestamp":1779886022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["v18060610"],"URL":"https:\/\/doi.org\/10.3390\/v18060610","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}